Angiorus (Tablets) Instructions for Use
ATC Code
C05CA53 (Diosmin in combination with other drugs)
Active Substances
Diosmin (Rec.INN registered by WHO)
Hesperidin (Grouping name)
Clinical-Pharmacological Group
Venotonic drug
Pharmacotherapeutic Group
Venotonic and venoprotective agent
Pharmacological Action
A combined agent with angioprotective and venotonic action, containing bioflavonoids.
It reduces venous distensibility, increases venous tone, and reduces venous stasis; decreases capillary permeability and fragility and increases their resistance; improves microcirculation and lymphatic drainage.
With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of organic and functional nature.
Indications
Symptomatic therapy of venous insufficiency of the lower extremities: sensation of heaviness and pain in the legs.
Symptomatic therapy of acute hemorrhoids.
ICD codes
| ICD-10 code | Indication |
| I87.2 | Venous insufficiency (chronic) (peripheral) |
| K64 | Hemorrhoids and perianal venous thrombosis |
| ICD-11 code | Indication |
| BD74.Z | Chronic venous insufficiency of lower extremities, unspecified |
| DB6Z | Hemorrhoids or perianal venous diseases, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets
For oral administration.
For veno-lymphatic insufficiency, the daily dose is 900 mg of diosmin + 100 mg of hesperidin. The frequency of administration is 2 times/day (at midday and in the evening during meals).
For acute hemorrhoids, during the first 4 days the daily dose is 2.7 g of diosmin + 300 mg of hesperidin (in 2 doses, morning and evening), during the following 3 days the daily dose is 1.8 g of diosmin + 200 mg of hesperidin (in 2 doses, morning and evening).
Adverse Reactions
From the digestive system: frequently – diarrhea, nausea, vomiting, dyspepsia; infrequently – colitis.
From the CNS rarely – dizziness, headache, general malaise.
From the skin: rarely – rash, itching, urticaria; unspecified frequency – isolated edema of the face, lips, eyelids; in exceptional cases – angioedema.
Contraindications
Lactation period (breastfeeding), hypersensitivity to diosmin and hesperidin.
Use in Pregnancy and Lactation
To date, there have been no reports of any side effects from the use of this combination in pregnant women.
Experimental studies have not observed teratogenic effects of the Diosmin+Hesperidin combination.
Contraindicated for use during lactation (breastfeeding), as it is unknown whether Diosmin and Hesperidin are excreted in breast milk.
Special Precautions
In case of hemorrhoid exacerbation, the use of this combination does not replace specific treatment for other anal disorders.
The duration of treatment should not exceed the recommended periods.
If symptoms do not disappear after short-term therapy, a proctological examination should be performed and the ongoing therapy should be reviewed.
In the presence of venous circulation disorders, the maximum treatment effect is achieved by combining it with a healthy, well-balanced lifestyle, which preferably includes avoiding prolonged sun exposure, prolonged standing, as well as reducing excess body weight, taking walks, and in some cases – wearing special stockings that improve blood circulation.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 60, or 90 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Manufactured By
Sintez PJSC (Russia)
Or
Aliym, JSC (Russia)
Dosage Form
| Angiorus | Film-coated tablets, 50 mg+450 mg: 20, 30, 40, 45, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets yellow-brown in color, biconvex, oval in shape; the appearance of the tablet on the break is from light yellow to grayish-yellow.
| 1 tab. | |
| Hesperidin | 50 mg |
| Diosmin | 450 mg |
Excipients : hypromellose (hydroxypropyl methylcellulose), lactose monohydrate (milk sugar), talc, colloidal silicon dioxide (aerosil), magnesium stearate, sodium carboxymethyl starch (sodium starch glycolate), microcrystalline cellulose.
Shell composition ready-made mixture for yellow film coating.
Composition of the ready-made mixture for yellow film coating macrogol-4000 (polyethylene glycol-4000), titanium dioxide, talc, polyvinyl alcohol, yellow iron oxide dye.
10 pcs. – contour cell packs (2, 3, 6) – cardboard packs×.
10 pcs. – contour cell packs (2, 3, 4, 6) – cardboard packs××.
15 pcs. – contour cell packs (2, 3, 4, 6) – cardboard packs××.
× manufactured by SINTEZ PJSC (Russia).
×× manufactured by ALIYM JSC (Russia).
Film-coated tablets, 100 mg+900 mg: 9, 10, 15, 18, 20, 27, 30, 36, 40, 45, 50, 54, 60, 63, 70, 72, 75, 80, 81, 90, 105, 120, or 135 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Manufactured By
Sintez PJSC (Russia)
Or
Aliym, JSC (Russia)
Dosage Form
| Angiorus | Film-coated tablets, 100 mg+900 mg: 9, 10, 15, 18, 20, 27, 30, 36, 40, 45, 50, 54, 60, 63, 70, 72, 75, 80, 81, 90, 105, 120, or 135 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets yellow-brown in color, biconvex, oval in shape; the appearance of the tablet on the break is from light yellow to grayish-yellow.
| 1 tab. | |
| Hesperidin | 100 mg |
| Diosmin | 900 mg |
Excipients : hypromellose, lactose monohydrate, talc, colloidal silicon dioxide, magnesium stearate, sodium carboxymethyl starch, microcrystalline cellulose.
Shell composition ready-made mixture for yellow film coating.
Composition of the ready-made mixture for yellow film coating macrogol-4000 (polyethylene glycol-4000), titanium dioxide, talc, polyvinyl alcohol, yellow iron oxide dye.
5 pcs. – contour cell packs (4, 6) – cardboard packs×.
10 pcs. – contour cell packs (2, 3, 6) – cardboard packs×.
15 pcs. – contour cell packs (2, 4) – cardboard packs×.
9 pcs. – contour cell packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs××.
10 pcs. – contour cell packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs××.
15 pcs. – contour cell packs (1, 2, 3, 4, 5, 6, 7, 8, 9) – cardboard packs××.
× manufactured by SINTEZ PJSC (Russia).
×× manufactured by ALIYM JSC (Russia).
